Theraclone Sciences Inc. announced results from a Phase 2a viral challenge study of TCN-032 for the universal treatment of influenza A. While the Phase 2a study did not meet its pre-specified primary endpoint, the overall data support an anti-influenza effect, the company said. In the study, TCN-032 treatment resulted in significant reductions in clinical symptoms score as well as viral load as compared to placebo-treated subjects.
TCN-032 is a recombinant, fully human monoclonal antibody that has the potential to treat patients who are hospitalized with serious influenza, as well as during pandemic outbreaks. The randomized, placebo-controlled, double-blind Phase 2a study was designed to assess the safety and efficacy of TCN-032 in normal human volunteers challenged with influenza A infection.
Theraclone is a biopharmaceutical company focused on the discovery and development of monoclonal antibody therapeutics. On August 1, 2013, Theraclone Sciences and PharmAthene (PIP) announced a definitive merger agreement.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.